Skip to main content
. 2021 Feb 26;57(3):210. doi: 10.3390/medicina57030210

Table A1.

Patient demographic and clinical data.

Characteristic n (%)
Age, years (mean, ±SD 1) 56.3 (44.8–67.8)
Gender:
Female 28 (40.0%)
Male 42 (60.0%)
BMI 2, kg/m2 27 (25–32)
<30 kg/m2 34 (48.6%)
≥30 kg/m2 23 (32.8%)
Unknown 13 (18.6%)
PAH 3
Yes 36 (51.4%)
No 34 (48.6%)
DM2 4
Yes 17 (24.3%)
No 53 (75.7%)
Alcohol abuse
Yes 21 (30.0%)
No 49 (70.0%)
Possible route of HCV 5 infection
Blood transfusion 19 (27.4%)
IV drug abuse 19 (27.4%)
Tattoo 15 (21.4%)
Surgical intervention 2 (2.8%)
Unknown 13 (21.0%)
HCV genotype
1 46 (65.7%)
2 4 (5.7%)
3 18 (25.7%)
HAI 6
4–8 55 (94.8%)
9–12 3 (5.2%)
METAVIR 8 (11.4%)
F3 F4 62 (88.6%)
Degree of steatosis (liver bioptate, median) 20% (7.0–30.0)
History of interferon-based treatment
No 51 (72.9%)
Yes 19 (27.1%)

1 SD—standard deviation; 2 BMI—body mass index; 3 PAH—primary arterial hypertension; 4 DM2—diabetes mellitus type 2; 5 HCV—hepatitis C virus; 6 HAI—histology activity index.